Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Short-term Investments (2016 - 2022)

Historic Short-term Investments for Iradimed (IRMD) over the last 10 years, with Q1 2022 value amounting to $500090.0.

  • Iradimed's Short-term Investments fell 7372.01% to $500090.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $500090.0, marking a year-over-year decrease of 7372.01%. This contributed to the annual value of $501855.0 for FY2021, which is 7371.62% down from last year.
  • According to the latest figures from Q1 2022, Iradimed's Short-term Investments is $500090.0, which was down 7372.01% from $501855.0 recorded in Q4 2021.
  • Iradimed's Short-term Investments' 5-year high stood at $8.2 million during Q2 2018, with a 5-year trough of $500090.0 in Q1 2022.
  • Over the past 5 years, Iradimed's median Short-term Investments value was $2.8 million (recorded in 2019), while the average stood at $3.6 million.
  • In the last 5 years, Iradimed's Short-term Investments surged by 1634.33% in 2018 and then plummeted by 7372.01% in 2022.
  • Over the past 5 years, Iradimed's Short-term Investments (Quarter) stood at $6.3 million in 2018, then tumbled by 56.4% to $2.8 million in 2019, then crashed by 31.03% to $1.9 million in 2020, then tumbled by 73.72% to $501855.0 in 2021, then fell by 0.35% to $500090.0 in 2022.
  • Its last three reported values are $500090.0 in Q1 2022, $501855.0 for Q4 2021, and $945066.0 during Q3 2021.